×
About 2,005 results

ALLMedicine™ Allergic Conjunctivitis Center

Research & Reviews  319 results

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
https://clinicaltrials.gov/ct2/show/NCT04207736

Jan 5th, 2022 - The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conju...

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
https://clinicaltrials.gov/ct2/show/NCT03479307

Dec 14th, 2021 - To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.

The relationship between allergic diseases and tic disorders: A systematic review and m...
https://doi.org/10.1016/j.neubiorev.2021.12.004
Neuroscience and Biobehavioral Reviews; Huang J, Li R et. al.

Dec 10th, 2021 - This systematic review aims to 1) explore the association between tic disorders (TD) and allergic diseases (AD), 2) judge whether patients with a diagnosis of TD are prone to suffer from a specific AD, by compiling the literature and analyzing the...

Kawasaki Disease and Atopic Diseases: A Systematic Review and Meta-Analysis of Observat...
https://doi.org/10.1159/000520045
International Archives of Allergy and Immunology; Wang Z, Zhang J et. al.

Nov 24th, 2021 - The etiology of Kawasaki disease (KD), an inflammatory and cardiovascular disorder, remains largely unexplained after more than 50 years of intensive research. In recent years, the association between KD and atopic diseases had been explored by so...

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
https://clinicaltrials.gov/ct2/show/NCT03231969

Nov 24th, 2021 - To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

see more →

Drugs  406 results see all →

Clinicaltrials.gov  34 results

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
https://clinicaltrials.gov/ct2/show/NCT04207736

Jan 5th, 2022 - The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conju...

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
https://clinicaltrials.gov/ct2/show/NCT03479307

Dec 14th, 2021 - To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
https://clinicaltrials.gov/ct2/show/NCT03231969

Nov 24th, 2021 - To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT04050865

Oct 7th, 2021 - The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
https://clinicaltrials.gov/ct2/show/NCT04037891

Mar 18th, 2021 - Recombinant rVA576 is a small protein (16.7kDa) which has two independent actions. It inhibits the activation and cleavage of complement C5 and it binds and inactivates leukotriene B4 (LTB4). It acts on the complement system by preventing the clea...

see more →

News  39 results

One in 15 Patients Who Start Dupilumab May Develop Conjunctivitis, Large Analysis Finds
https://www.medscape.com/viewarticle/953387

Jun 18th, 2021 - One in 15 patients who start dupilumab treatment may develop conjunctivitis during the first 6 months, most of which is manageable with ophthalmic treatments, results from large study of U.S. claims data showed. "About 4 years after dupilumab's ap...

Allergic Conjunctivitis Severely Affects Children's Quality of Life
https://www.medscape.com/viewarticle/953091

Jun 15th, 2021 - Allergic conjunctivitis harms quality of life for children and their parents, apparently causing greater day-to-day worries than potentially blinding diseases, researchers report. Parents worry especially that treatments might not be effective, ac...

BRIEF-Aldeyra Therapeutics Q1 Loss Per Share $0.34
https://www.reuters.com/article/brief-aldeyra-therapeutics-q1-loss-per-s/brief-aldeyra-therapeutics-q1-loss-per-share-0-34-idUSASA00OI1

May 7th, 2020 - May 7 (Reuters) - Aldeyra Therapeutics Inc: * ALDEYRA THERAPEUTICS REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND ANNOUNCES NEW CLINICAL PROGRAMS * Q1 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA * ADX-629 EXPECTED TO BEGIN PHASE 2 ...

Epinephrine-Coated Syringes Curb Local Reactions to Immunotherapy
https://www.medscape.com/viewarticle/922769

Dec 18th, 2019 - NEW YORK (Reuters Health) - Using epinephrine-coated syringes for subcutaneous immunotherapy (SCIT) lowers the risk of local reactions such as erythema and swelling at injection sites, according to researchers in Thailand. Such syringes, Dr. Orath...

Fast Five Quiz: Allergy Triggers
https://reference.medscape.com/viewarticle/917113_4

Aug 23rd, 2019 - Immediate hypersensitivity skin testing is the most useful method to detect immunoglobulin E antibody against mold allergens. Testing can be performed by using the prick or intradermal method. The preferred sites are the upper part of the back for...

see more →

Patient Education  4 results see all →